Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PAM | P19021 | 1/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852083 | 0.89 | MEN1 (0.56) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL1137350 | 0.89 | ALDH1A1 (0.67) | ALDH1A1MAPK1L3MBTL1PRKCAPRKCD | |
| SCHEMBL490786 | 0.86 | MEN1 (0.59) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL20867886 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MAPK1L3MBTL1PRKCAPRKCD | |
| SCHEMBL2658123 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MAPK1L3MBTL1PRKCAPRKCD | |
| SCHEMBL28207459 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MAPK1L3MBTL1PRKCAPRKCD | |
| SCHEMBL9205647 | 0.85 | MEN1 (0.67) | MEN1KMT2ALTB4RLTB4R2NR4A2 | |
| SCHEMBL2957881 | 0.85 | MEN1 (0.67) | MEN1KMT2ALTB4RLTB4R2NR4A2 | |
| SCHEMBL16348239 | 0.83 | MEN1 (0.65) | MEN1KMT2ALTB4RLTB4R2NR4A2 | |
| SCHEMBL8051693 | 0.83 | NR1H4 (0.51) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396455-A | Resorcinol, its manufacturing method and use | 吉伟研究有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022238707-A1 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | GW Research Limited (GB) | 2022-11-17 | — | — | WO | disclosed |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9611213-B2 | Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | KANNALIFE SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | KANNALIFE SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | TXNRD2, KEAP1, GOT2 | ALDH1A1 195/4885MAPK1 1444/4885L3MBTL1 3909/4885 |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | EPHX1, DBH, EPHX2 | ALDH1A1 197/4885MAPK1 3104/4885L3MBTL1 3561/4885 |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | TXNRD2, KEAP1, GOT2 | ALDH1A1 195/4885MAPK1 1444/4885L3MBTL1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.